Effect of hemoglobin, albumin, lymphocyte, and platelet score on prognosis in intermediate-risk endometrial cancer according to molecular-based classification

Basit Öğe Kaydı
dc.authoridDUR, RIZA/0000-0002-9225-9030
dc.authoridOzdemir, Cem Yagmur/0000-0001-5560-2162
dc.contributor.authorOzdemir, Cem Yagmur
dc.contributor.authorCicekli, Nayif
dc.contributor.authorAhat, Betul
dc.contributor.authorMarangoz, Bahar
dc.contributor.authorKonus, Suleyman
dc.contributor.authorDur, Riza
dc.contributor.authorArioz, Dagistan Tolga
dc.date.accessioned2025-01-27T21:13:41Z
dc.date.available2025-01-27T21:13:41Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectiveThe aim of this study is to compare the relationship between molecular classification and HALP score in endometrial cancer (EC).MethodsPatients who were operated with the diagnosis of EC 2014 and 2024 were included in our study. 150 patients were included in the study. We divided the patients into three groups in terms of molecular classification; group 1 was the patients with POLE mutation, group 2 was the patients with MMRd and NSMP (intermediate prognosis), and group 3 was the patients with p53 mutation. Group 2 participants were divided into two groups, a low HALP score group and a high HALP score group, according to the HALP score cut-off value.ResultsUsing the value with the highest Youden's index (0.306) as a basis, it was demonstrated that the HALP score with a cut-off value of 33.735 has a sensitivity of 61.86% and a specificity of 68.75% in intermediate-risk EC. The 5-year overall survival (OS) was found to be 75.4% in intermediate-risk EC patients with low HALP scores and 91.5% in intermediate-risk EC patients with high HALP scores (p = 0.008). The 5-year progression-free survival (PFS) was found to be 86% in intermediate-risk EC patients with low HALP scores and 94.4% in intermediate-risk EC patients with high HALP scores (p = 0.089). MMR deficiency and NSMP have been considered intermediate-risk groups for endometrial cancer and are a heterogeneous group. Although the use of the HALP score to reduce this heterogeneity is successful in predicting OS, it is not sufficient for PFS.
dc.identifier.doi10.1111/jog.16103
dc.identifier.endpage2112
dc.identifier.issn1341-8076
dc.identifier.issn1447-0756
dc.identifier.issue11
dc.identifier.pmid39351859
dc.identifier.scopus2-s2.0-85205475993
dc.identifier.scopusqualityQ2
dc.identifier.startpage2107
dc.identifier.urihttps://doi.org/10.1111/jog.16103
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28495
dc.identifier.volume50
dc.identifier.wosWOS:001322612900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Obstetrics and Gynaecology Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectendometrial cancer
dc.subjectHALP score
dc.subjectprognosis
dc.titleEffect of hemoglobin, albumin, lymphocyte, and platelet score on prognosis in intermediate-risk endometrial cancer according to molecular-based classification
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu